Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2022 - 03 - 08    tags : Trial    save search

Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting
Published: 2022-03-08 (Crawled : 00:00) - biospace.com/
RPTX 4 | $3.14 3.97% 3.82% 220K twitter stocktwits trandingview |
Health Technology
| | O: -2.02% H: 0.0% C: 0.0%

rp-3500 500 trial therapeutics phase 1 therapy phase 2 phase 3
Altra Industrial Motion Corp. to Host Investor Day Providing New Long-Term Strategy for Delivering Profitable Growth
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
AIMC | $61.98 -0.02% 0.0% 0 twitter stocktwits trandingview |
Producer Manufacturing
| | O: 1.0% H: 2.91% C: -1.74%

day liver trial growth
Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
BXRX | $0.1864 -54.35% 330K twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 2.49% C: 1.25%

anjeso trial
Rackspace Technology Works with Delta Thermal to Help Electric Utilities and Downstream Industrial Customers Protect and Grow the Power Grid with AWS
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
RXT | $1.61 2.55% 2.48% 2.4M twitter stocktwits trandingview |
Technology Services
| | O: 2.22% H: 3.05% C: -0.39%

space technology trial work spac
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
RUBY | $0.057 -99.3% 760K twitter stocktwits trandingview |
Health Technology
| | O: 2.12% H: 20.58% C: 19.33%

rtx-240 america research trial therapeutics phase 1 results cancer
American Airlines to Present at 2022 J.P. Morgan Industrials Conference
Published: 2022-03-08 (Crawled : 21:00) - globenewswire.com
AAL | $14.1 0.57% 0.57% 27M twitter stocktwits trandingview |
Transportation
| | O: 6.88% H: 2.15% C: -0.97%

america als air trials trial conference
General Dynamics Chairman and CEO to speak at the 2022 J.P. Morgan Industrials Conference
Published: 2022-03-08 (Crawled : 18:00) - prnewswire.com
GD | $288.61 1.17% 650K twitter stocktwits trandingview |
Electronic Technology
| | O: 0.04% H: 0.19% C: -4.88%

als air trials ceo trial conference
LyondellBasell to Address J.P. Morgan Industrials Conference
Published: 2022-03-08 (Crawled : 18:00) - prnewswire.com
LYB | News | $100.74 1.35% 0.0% 2M twitter stocktwits trandingview |
Process Industries
| | O: -1.62% H: 2.5% C: 0.59%

als trials trial conference
FCFS 7-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages FirstCash (FCFS) Investors with Losses to Contact Firm's Attorneys Before Mar. 15th Deadline in Securities Class Action
Published: 2022-03-08 (Crawled : 15:00) - prnewswire.com
FCFS 4 | $130.42 1.32% 1.3% 220K twitter stocktwits trandingview |
Finance
| | O: -6.61% H: 0.94% C: -3.13%

day trial deadline
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
Published: 2022-03-08 (Crawled : 13:30) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K twitter stocktwits trandingview |
Health Technology
| | O: -8.33% H: 4.55% C: 0.45%

ces derm trial presentation
Reliance Steel & Aluminum Co. Announces Participation at the J.P. Morgan 2022 Industrials Conference
Published: 2022-03-08 (Crawled : 12:00) - globenewswire.com
RS | $319.25 -0.28% 130K twitter stocktwits trandingview |
Non-Energy Minerals
| | O: -2.92% H: 1.17% C: -0.69%

als trials trial conference
CNH Industrial strengthens its presence in India with state-of-the-art Technology Center
Published: 2022-03-08 (Crawled : 11:00) - globenewswire.com
CNHI | News | $12.31 -0.73% 0.0% 6.9M twitter stocktwits trandingview |
Producer Manufacturing
| | O: -0.25% H: 3.58% C: 1.29%

state technology trial india
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
Published: 2022-03-08 (Crawled : 07:00) - inventivapharma.com
IVA | $3.35 -2.9% 8.5K twitter stocktwits trandingview |
Health Technology
| | O: -0.18% H: 2.55% C: 1.91%

fda application ces trial nash
Gainers vs Losers
65% 35%

Top 10 Gainers
AGBA | News | $1.305 226.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

INSG | $3.03 25.21% 330K twitter stocktwits trandingview |
Electronic Technology

KNW 4 | $0.59 -0.71% 18.64% 27K twitter stocktwits trandingview |
Manufacturing

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.